Interest of positron-emission tomography and magnetic resonance imaging for radiotherapy planning and control.
Interest of positron-emission tomography and magnetic resonance imaging for radiotherapy planning and control. Cancer Radiother. 2020 Apr 01;: Authors: Créhange G, Soussan M, Gensanne D, Decazes P, Thariat J, Thureau S Abstract Computed tomography (CT) in the treatment position is currently indispensable for planning radiation therapy. Other imaging modalities, such as magnetic resonance imaging (MRI) and positron emission-tomography (PET), can be used to improve the definition of the tumour and/or healthy tissue but also to provide functional data of the target volume. Accurate image registration is essential for treatment planning, so MRI and PET scans should be registered at the planning CT scan. Hybrid PET/MRI scans with a hard plane can be used but pose the problem of the absence of CT scans. Finally, techniques for moving the patient on a rigid air-cushioned table allow PET/CT/MRI scans to be performed in the treatment position while limiting the patient's movements exist. At the same time, the advent of MRI-linear accelerator systems allows to redefine image-guided radiotherapy and to propose treatments with daily recalculation of the dose. The place of PET during treatment remains more confidential and currently only in research and prototype status. The same development of imaging during radiotherapy is underway in proton therapy. PMID: 32247688 [PubMed - as supplied by publisher]
Publication date: Available online 30 May 2020Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral RadiologyAuthor(s): Kevin C. Lee, Sung-Kiang Chuang
Publication date: Available online 30 May 2020Source: Pharmacological ResearchAuthor(s): Ling Wang, Ke Deng, Liang Gong, Liang Zhou, Sapna Sayed, Huan Li, Qi Sun, Zijie Su, Zhongyuan Wang, Shanshan Liu, Huifang Zhu, Jiaxing Song, Desheng Lu
Publication date: Available online 31 May 2020Source: Pharmacology &TherapeuticsAuthor(s): Jie Yu, Bingling Zhong, Qingwen Xiao, Lida Du, Ying Hou, Hong-Shuo Sun, Jin-Jian Lu, Xiuping Chen
Publication date: Available online 31 May 2020Source: Pharmacology &TherapeuticsAuthor(s): Kevin M. Levine, Kai Ding, Lyuqin Chen, Steffi Oesterreich
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Qi Chen, Huachao Xu, Jiang Zhu, Kehai Feng, Changlu Hu
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Celso Alves, Eurico Serrano, Joana Silva, Carlos Rodrigues, Susete Pinteus, Helena Gaspar, Luis M. Botana, Maria C. Alpoim, Rui Pedrosa
Publication date: Available online 30 May 2020Source: PhytomedicineAuthor(s): Weihuan Huang, Yeyin Liang, Hau Yin Chung, Guocai Wang, Jim Junhui Huang, Yaolan Li
CONCLUSIONS: An approach to standardise current dose modification schemes in young children is proposed. The consented concept takes individual pharmacokinetic characteristics into account and involves adaptation of both the dose and the infusion duration potentially improving the safety of doxorubicin administration. PMID: 32466789 [PubMed - in process]
Osborne H Abstract The calcium-sensing receptor (CaSR) is a class C G protein-coupled receptor that responds to multiple endogenous agonists and allosteric modulators, including divalent and trivalent cations, L-amino acids, γ-glutamyl peptides, polyamines, polycationic peptides, and protons. The CaSR plays a critical role in extracellular calcium (Ca2+ o) homeostasis, as demonstrated by the many naturally occurring mutations in the CaSR or its signaling partners that cause Ca2+ o homeostasis disorders. However, CaSR tissue expression in mammals is broad and includes tissues unrelated to Ca2+ o homeostasis, ...
Publication date: Available online 30 May 2020Source: Seminars in Cancer BiologyAuthor(s): María González González, María Laura Gutiérrez, José María Sayagués, Luis Muñoz-Bellvís, Alberto Orfao